Given the observed delayed compensatory response in the alternative RAS axis components within heart tissues during cholestasis, studies exploring the early administration of MasR agonists to mitigate the acute detrimental effects of angiotensin 2 on both hepatic and cardiac functions are warranted. Here, MAS1L is linked to cholestasis.